Search research articles
Contact Us
Filters
Showing results (81-90 of 106) with videos related to
Page
of 11
Sort By:
Plos One
|
July 7, 2015
Potent and Selective Triazole-Based Inhibitors of the Hypoxia-Inducible Factor Prolyl-Hydroxylases with Activity in the Murine Brain
Mun Chiang Chan, Onur Atasoylu, Emma Hodson, et al.
Nature Chemistry
|
April 15, 2026
KDM3A catalyses the oxidation of acetyl-lysine to hydroxyacetyl-lysine on histone H3K9
Roman Belle, John-Paul Bukowski, Rachel Schiller, et al.
Angewandte Chemie (International Ed. in English)
|
May 14, 2014
A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation-π interaction
Timothy P C Rooney, Panagis Filippakopoulos, Oleg Fedorov, et al.
Journal of the American Chemical Society
|
June 20, 2014
Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains
Duncan A Hay, Oleg Fedorov, Sarah Martin, et al.
Science Advances
|
June 21, 2023
Accelerating drug target inhibitor discovery with a deep generative foundation model
Vijil Chenthamarakshan, Samuel C Hoffman, C David Owen, et al.
ACS Chemical Biology
|
May 21, 2013
Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases
Rasheduzzaman Chowdhury, José Ignacio Candela-Lena, Mun Chiang Chan, et al.
Angewandte Chemie (International Ed. in English)
|
October 5, 2017
Discovery of a Highly Selective Cell-Active Inhibitor of the Histone Lysine Demethylases KDM2/7
Philip A Gerken, Jamie R Wolstenhulme, Anthony Tumber, et al.
Journal of Medicinal Chemistry
|
November 29, 2021
First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53
Radosław P Nowak, Anthony Tumber, Eline Hendrix, et al.
Nature Chemical Biology
|
May 24, 2016
Structural analysis of human KDM5B guides histone demethylase inhibitor development
Catrine Johansson, Srikannathasan Velupillai, Anthony Tumber, et al.
Chemical Science
|
February 14, 2018
Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials
Tzu-Lan Yeh, Thomas M Leissing, Martine I Abboud, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 106) with videos related to
Sort By:
Page
of 11
Plos One
|
July 7, 2015
Potent and Selective Triazole-Based Inhibitors of the Hypoxia-Inducible Factor Prolyl-Hydroxylases with Activity in the Murine Brain
Mun Chiang Chan, Onur Atasoylu, Emma Hodson, et al.
Nature Chemistry
|
April 15, 2026
KDM3A catalyses the oxidation of acetyl-lysine to hydroxyacetyl-lysine on histone H3K9
Roman Belle, John-Paul Bukowski, Rachel Schiller, et al.
Angewandte Chemie (International Ed. in English)
|
May 14, 2014
A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation-π interaction
Timothy P C Rooney, Panagis Filippakopoulos, Oleg Fedorov, et al.
Journal of the American Chemical Society
|
June 20, 2014
Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains
Duncan A Hay, Oleg Fedorov, Sarah Martin, et al.
Science Advances
|
June 21, 2023
Accelerating drug target inhibitor discovery with a deep generative foundation model
Vijil Chenthamarakshan, Samuel C Hoffman, C David Owen, et al.
ACS Chemical Biology
|
May 21, 2013
Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases
Rasheduzzaman Chowdhury, José Ignacio Candela-Lena, Mun Chiang Chan, et al.
Angewandte Chemie (International Ed. in English)
|
October 5, 2017
Discovery of a Highly Selective Cell-Active Inhibitor of the Histone Lysine Demethylases KDM2/7
Philip A Gerken, Jamie R Wolstenhulme, Anthony Tumber, et al.
Journal of Medicinal Chemistry
|
November 29, 2021
First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53
Radosław P Nowak, Anthony Tumber, Eline Hendrix, et al.
Nature Chemical Biology
|
May 24, 2016
Structural analysis of human KDM5B guides histone demethylase inhibitor development
Catrine Johansson, Srikannathasan Velupillai, Anthony Tumber, et al.
Chemical Science
|
February 14, 2018
Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials
Tzu-Lan Yeh, Thomas M Leissing, Martine I Abboud, et al.
Page
of 11